Mr. Andy Liu is an Operational Executive with strong P&L experience.
He has spent many years with Private Equity & Venture Capital firms operating portfolio companies in healthcare and pharmaceutical industries.

 

Mr. Andy A. Liu is currently the Group CEO of Cellomics Holdings, the leader in liquid biopsy technology for cancer screening and precision diagnostics. Mr. Liu has held several executive roles previously including the President of Basebit Technologies, CEO of CW Data Technologies and CEO of Ilumi Health.

 

Mr. Liu was also previously the President of Asia Pacific and China for IQVia. (Previously known as IMS Health) Mr. Liu managed the Data Analytics, Digital Solutions, and Commerical and Consulting businesses for the entire Asia Pacific. Mr. Liu was responsible for managing the P&L of the entire region inclusive of 17 countries including China, Australia, India, South Korea, New Zealand, Hong Kong, Taiwan, Vietnam, Indonesia, Philippines, Thailand, Singapore, Malaysia, Taiwan, Bangladesh, Sri Lanka and Pakistan.

 

Mr. Liu has spent many years with multinational companies such as Merck and UCB Pharma holding several executive management and leadership positions in the USA and Asia. Mr. Liu has also spent many years with private equity firm TPG as an operator running TPG portfolio companies including IMS and Moksha8.

 

Mr. Liu's area of focus is in healthcare product launch and commercialization: inclusive of regulatory approval, pricing, customer acquisition, marketing and sales execution. He has successfully managed and launched products across key therapeutic franchises such as hypertension, atherosclerosis, anticonvulsants, arthritis, antihistamine, osteoporosis and diabetes. He also has strong experience in deal transactions, investments, joint ventures and mergers and acquisitions in the life sciences sector.

He has also served as the Board of Directors of ASTRI and HKBIO